Maravai LifeSciences Competitors

BeiGene (NASDAQ:BGNE) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Institutional & Insider Ownership

60.7% of BeiGene shares are held by institutional investors. 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BeiGene and Maravai LifeSciences' gross revenue, earnings per share and valuation.

Maravai LifeSciences has lower revenue, but higher earnings than BeiGene.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BeiGene and Maravai LifeSciences, as provided by MarketBeat.com.

BeiGene presently has a consensus target price of $317.1250, indicating a potential upside of 4.55%. Maravai LifeSciences has a consensus target price of $38.1250, indicating a potential upside of 6.43%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than BeiGene.

Profitability

This table compares BeiGene and Maravai LifeSciences' net margins, return on equity and return on assets.

Summary

Maravai LifeSciences beats BeiGene on 6 of the 9 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Maravai LifeSciences (NASDAQ:MRVI) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Royalty Pharma and Maravai LifeSciences, as provided by MarketBeat.

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 25.03%. Maravai LifeSciences has a consensus target price of $38.1250, suggesting a potential upside of 6.43%. Given Royalty Pharma's higher probable upside, equities research analysts clearly believe Royalty Pharma is more favorable than Maravai LifeSciences.

Profitability

This table compares Royalty Pharma and Maravai LifeSciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Royalty Pharma and Maravai LifeSciences' revenue, earnings per share and valuation.

Summary

Royalty Pharma beats Maravai LifeSciences on 3 of the 5 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Genmab A/S, as reported by MarketBeat.

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Genmab A/S has a consensus price target of $41.5714, suggesting a potential upside of 11.63%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Genmab A/S's net margins, return on equity and return on assets.

Institutional & Insider Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Genmab A/S's top-line revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than Maravai LifeSciences.

Summary

Genmab A/S beats Maravai LifeSciences on 6 of the 8 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and CureVac, as reported by MarketBeat.

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. CureVac has a consensus price target of $58.3333, suggesting a potential downside of 44.86%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than CureVac.

Profitability

This table compares Maravai LifeSciences and CureVac's net margins, return on equity and return on assets.

Institutional & Insider Ownership

4.3% of CureVac shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and CureVac's top-line revenue, earnings per share (EPS) and valuation.

Summary

Maravai LifeSciences beats CureVac on 3 of the 4 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Horizon Therapeutics Public, as reported by MarketBeat.

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Horizon Therapeutics Public has a consensus price target of $111.3636, suggesting a potential upside of 29.13%. Given Horizon Therapeutics Public's higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Institutional & Insider Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Horizon Therapeutics Public's top-line revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Maravai LifeSciences.

Summary

Horizon Therapeutics Public beats Maravai LifeSciences on 8 of the 8 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Catalent (NYSE:CTLT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Catalent's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Maravai LifeSciences and Catalent, as reported by MarketBeat.

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.43%. Catalent has a consensus price target of $125.1250, suggesting a potential upside of 19.39%. Given Catalent's higher probable upside, analysts plainly believe Catalent is more favorable than Maravai LifeSciences.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Maravai LifeSciences and Catalent's top-line revenue, earnings per share (EPS) and valuation.

Catalent has higher revenue and earnings than Maravai LifeSciences.

Summary

Catalent beats Maravai LifeSciences on 7 of the 9 factors compared between the two stocks.